Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology · Post-Transplant Cancer Risk

Cancer Risk and Surveillance: Staying Proactive After Transplant

At a Glance

Taking immunosuppressive medications after an organ transplant increases your risk for certain cancers, particularly skin cancer and PTLD. Practicing daily sun protection and attending regular dermatology and viral screenings are essential to catch and treat these conditions early.

A healthy immune system does more than fight infections; it also acts as a “security guard” that finds and destroys abnormal cells before they can turn into cancer. Because you take immunosuppressive medications to protect your transplant, this natural cancer surveillance is lowered [1][2]. While this increases certain risks, being proactive with screening and prevention can help catch issues early when they are most treatable.

Skin Cancer: The Most Common Risk

Skin cancer is the most common type of cancer seen after a transplant [3][4].

  • Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC): These “non-melanoma” skin cancers are driven by both sun exposure and the length of time you have been on immunosuppression [2][5]. Certain medications, like azathioprine, may make your skin even more sensitive to UV damage [6].
  • Melanoma: While less common than SCC, transplant recipients also have an increased risk for melanoma, making it vital to monitor all moles and skin changes [7].
  • Prevention: You should wear high-SPF sunscreen daily, avoid peak sun hours, and wear protective clothing [5]. An annual (or semi-annual) full-body skin check by a dermatologist is essential [8].

Understanding PTLD and the EBV Link

Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious but manageable condition where certain white blood cells (B-cells) grow out of control. It is almost always linked to the Epstein-Barr Virus (EBV)—the same virus that causes “mono” [9].

  • The EBV Balance: Most adults already carry EBV. Normally, your T-cells keep the virus in check. When T-cells are suppressed by transplant medications (like ATG), EBV can wake up and cause B-cells to multiply rapidly [9][10].
  • High-Risk Patients: You are at the highest risk if you were never exposed to EBV before your transplant but your donor was (known as D+/R-). Because your body has no pre-existing immunity, a new EBV infection can be more aggressive [9][11].
  • Monitoring: Your team will likely use EBV-DNA PCR blood tests to monitor your viral load [12][13]. If the virus levels start to rise, they may proactively lower your immunosuppression or use other therapies to prevent PTLD from developing [12][14].

A Proactive Surveillance Plan

Cancer screening for transplant recipients is more rigorous and personalized than for the general public [15].

  • Dermatology: A full-body exam every 6 to 12 months [8].
  • Viral Monitoring: Regular blood tests for EBV and potentially other viruses like CMV or HPV [14].
  • General Screenings: You should stay current on standard screenings, such as colonoscopies, mammograms, and Pap smears, as directed by your team [16][17].
  • Medication Adjustments: In some cases, your doctor may switch you to mTOR inhibitors (like sirolimus), which have been shown to have “anti-tumor” properties and may reduce the risk of certain cancers [18][19].

By staying consistent with your appointments and practicing sun safety, you can significantly reduce these long-term risks and protect your health for years to come.

Common questions in this guide

Why am I at a higher risk for cancer after an organ transplant?
The immunosuppressive medications you take to prevent organ rejection also lower your immune system's natural ability to detect and destroy abnormal cells. This reduced cancer surveillance makes you more vulnerable to developing certain types of cancer over time.
Which type of cancer is most common for transplant recipients?
Skin cancer is the most common cancer after a transplant, particularly squamous cell and basal cell carcinomas. The risk increases based on your history of sun exposure and the length of time you have been taking immunosuppression medications.
What is PTLD and how is it related to EBV?
Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious condition where certain white blood cells grow out of control. It is almost always triggered by the Epstein-Barr Virus (EBV) waking up when your immune system is suppressed by transplant medications.
How do doctors monitor my risk for PTLD?
Your healthcare team will regularly check your blood using an EBV-DNA PCR test to monitor your viral load. If your EBV levels begin to rise, they can proactively adjust your immunosuppression to help prevent PTLD from developing.
What steps can I take to prevent skin cancer after my transplant?
You should apply a high-SPF sunscreen daily, avoid the sun during peak UV hours, and wear protective clothing. Additionally, you must see a dermatologist every six to twelve months for a full-body skin exam to catch any changes early.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my EBV status (and my donor's), how often will I have my EBV viral load monitored?
  2. 2.Can you recommend a transplant-specialist dermatologist for my annual skin checks?
  3. 3.If my EBV levels start to rise, what is our 'preemptive' plan to prevent PTLD?
  4. 4.Are there specific medications I am taking, like azathioprine, that significantly increase my skin cancer risk?
  5. 5.How does my cancer screening schedule differ from someone who hasn't had a transplant?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Cancer mortality among solid organ transplant recipients: A systematic review and meta-analysis.

    Wang Z, Deng L, Hou W, et al.

    Preventive medicine 2024; (189()):108161 doi:10.1016/j.ypmed.2024.108161.

    PMID: 39491730
  2. 2

    Non-Melanoma Skin Cancer in Transplant Recipients: A Single-Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes.

    Zengarini C, Tagnin V, Sorbi G, et al.

    Clinical transplantation 2026; (40(2)):e70451 doi:10.1111/ctr.70451.

    PMID: 41615235
  3. 3

    Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? a systematic review and meta-analysis.

    Genders RE, Weijns ME, Dekkers OM, Plasmeijer EI

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(5)):828-841 doi:10.1111/jdv.15396.

    PMID: 30793804
  4. 4

    Malignancy after lung transplantation.

    Shtraichman O, Ahya VN

    Annals of translational medicine 2020; (8(6)):416 doi:10.21037/atm.2020.02.126.

    PMID: 32355860
  5. 5

    Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40 year retrospective study in Croatia.

    Bašić-Jukić N, Borlinić T, Tešanović D, et al.

    Croatian medical journal 2022; (63(2)):148-155.

    PMID: 35505648
  6. 6

    Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis.

    Kreuz M, Cardoso JCO, Sobreira LER, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025; (27(7)):3100-3109 doi:10.1007/s12094-024-03839-0.

    PMID: 39825996
  7. 7

    Non-melanoma skin cancer of the head and neck.

    Roland N, Memon A

    British journal of hospital medicine (London, England : 2005) 2023; (84(4)):1-10 doi:10.12968/hmed.2021.0126.

    PMID: 37127417
  8. 8

    Non-melanoma skin cancer in Portuguese kidney transplant recipients - incidence and risk factors.

    Pinho A, Gouveia M, Cardoso JC, et al.

    Anais brasileiros de dermatologia 2016; (91(4)):455-62.

    PMID: 27579740
  9. 9

    The promise of a prophylactic Epstein-Barr virus vaccine.

    Balfour HH, Schmeling DO, Grimm-Geris JM

    Pediatric research 2020; (87(2)):345-352 doi:10.1038/s41390-019-0591-5.

    PMID: 31641280
  10. 10

    Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.

    Lindsay J, Othman J, Yong MK, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2021; (23(5)):e13719 doi:10.1111/tid.13719.

    PMID: 34453768
  11. 11

    Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients.

    Pollack S, Plonsky M, Tibi R, et al.

    Pediatric nephrology (Berlin, Germany) 2025; (40(3)):829-834 doi:10.1007/s00467-024-06522-2.

    PMID: 39373867
  12. 12

    Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.

    Colombini E, Guzzo I, Morolli F, et al.

    Pediatric nephrology (Berlin, Germany) 2017; (32(8)):1433-1442 doi:10.1007/s00467-017-3627-2.

    PMID: 28280938
  13. 13

    Analysis of risk factors for Epstein-Barr virus reactivation and progression to post-transplant lymphoproliferative disorder in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

    Jia L, Yang H, Zhou Y, et al.

    Frontiers in pediatrics 2025; (13()):1627990 doi:10.3389/fped.2025.1627990.

    PMID: 40746349
  14. 14

    Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.

    Fujimoto A, Hiramoto N, Yamasaki S, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(7)):1441-1449 doi:10.1016/j.bbmt.2019.02.016.

    PMID: 30794929
  15. 15

    Advanced Leiomyosarcoma of the Retroperitoneal Space in a Kidney Transplant Recipient with a History of Peritoneal Dialysis: A Case Report.

    Kaźmierczak O, Kozaczka A, Kolonko A, et al.

    The American journal of case reports 2021; (22()):e933267 doi:10.12659/AJCR.933267.

    PMID: 34695070
  16. 16

    Post-transplant malignancy in solid organ transplant recipients in Ireland, The Irish Transplant Cancer Group.

    O'Neill JP, Sexton DJ, O'Leary E, et al.

    Clinical transplantation 2019; (33(10)):e13669 doi:10.1111/ctr.13669.

    PMID: 31310037
  17. 17

    Risk of Colorectal Cancer After Solid Organ Transplantation in the United States.

    Safaeian M, Robbins HA, Berndt SI, et al.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2016; (16(3)):960-7 doi:10.1111/ajt.13549.

    PMID: 26731613
  18. 18

    Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation.

    Asleh R, Alnsasra H, Habermann TM, et al.

    Frontiers in cardiovascular medicine 2022; (9()):787975 doi:10.3389/fcvm.2022.787975.

    PMID: 35282339
  19. 19

    Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors.

    Petrara MR, Serraino D, Di Bella C, et al.

    Cancer letters 2020; (469()):323-331 doi:10.1016/j.canlet.2019.10.045.

    PMID: 31693921

This page provides educational information about cancer risks and surveillance after an organ transplant. It is not a substitute for professional medical advice, and you should always consult your transplant team regarding your specific screening and prevention plan.

Get notified when new evidence is published on Complication after organ transplantation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.